1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/35583
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOpat S.en
dc.contributor.authorTrotman J.en
dc.contributor.authorThorburn A.N.en
dc.contributor.authorBoulos J.en
dc.contributor.authorTam C.en
dc.contributor.authorCheah C.Y.en
dc.contributor.authorDickinson M.en
dc.date.accessioned2021-05-14T12:01:39Zen
dc.date.available2021-05-14T12:01:39Zen
dc.date.copyright2019en
dc.date.created20190515en
dc.date.issued2019-05-15en
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology. 15 (S3) (pp 3-11), 2019. Date of Publication: May 2019.en
dc.identifier.issn1743-7555en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/35583en
dc.description.abstractRecently, obinutuzumab was included in the Australian Pharmaceutical Benefits Scheme for use in first line, advanced or bulky stage 2, follicular lymphoma, providing more immunochemotherapy treatment options available than ever before. Rituximab with chemotherapy has been the standard of care since reimbursement in the late 1990s; however, obinutuzumab-based regimens have shown superior progression-free survival in comparison to rituximab-based options, albeit at an increased risk of grade >=3 adverse events. As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.Copyright © 2019 John Wiley & Sons Australia, Ltden
dc.languageEnglishen
dc.languageenen
dc.publisherBlackwell Publishing Ltden
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncologyen
dc.titleManagement of patients with follicular lymphoma treated first line with obinutuzumab.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajco.13153en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid31058467 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31058467]en
dc.identifier.source627559129en
dc.identifier.institution(Opat) School of Clinical Sciences, Monash Health, Monash University, Clayton, Melbourne, VIC, Australia (Dickinson, Tam) Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Cheah) Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia (Tam) Department of Haematology, St Vincent's Hospital, Melbourne, VIC, Australia (Boulos, Thorburn) Roche Products Pty Ltd, Sydney, NSW, Australia (Trotman) Haematology Department, Concord Hospital, University of Sydney, Concord, NSW, Australiaen
dc.description.addressS. Opat, School of Clinical Sciences, Monash Health, Monash University, Clayton, Melbourne, VIC, Australia. E-mail: Stephen.Opat@monashhealth.orgen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.subect.keywordschemoimmunotherapy follicular lymphoma obinutuzumab rituximaben
dc.identifier.authoremailOpat S.; Stephen.Opat@monashhealth.orgen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

8
checked on Sep 11, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.